key: cord-0986659-4oo2ejwe
authors: Lim, Rachel K.; Kalagara, Saisanjana; Chen, Kenneth K.; Mylonakis, Eleftherios; Kroumpouzos, George
title: DERMATOLOGY IN A MULTIDISCIPLINARY APPROACH WITH INFECTIOUS DISEASE AND OBSTETRIC MEDICINE AGAINST COVID-19
date: 2021-08-26
journal: Int J Womens Dermatol
DOI: 10.1016/j.ijwd.2021.08.008
sha: ff0eae5d49edf8ff6fd0653f5d479c6ac1e37f8a
doc_id: 986659
cord_uid: 4oo2ejwe

Coronavirus disease 2019 (COVID-19) care requires a team approach, and dermatologists may collaborate with other specialties, especially infectious disease (ID) medicine and obstetrics and gynecology (ObGyn) at every stage of the infection process. A broad spectrum of cutaneous manifestations may occur early in COVID-19, making appropriate dermatologic identification critical for early diagnosis. There is prognostic value in appropriately identifying different types of COVID-19-associated skin manifestations which have been linked to disease severity. Such observations emanated from dermatology research, especially large series and international registry of cutaneous manifestations relating to COVID-19, and impact COVID-19 care provided by most healthcare providers. Also, research based on international registry of skin reactions from COVID-19 vaccines is having an impact across disciplines. An increased risk for severe illness from COVID-19 is encountered in pregnancy, and dermatologists’ role is to urge ObGyn and other clinicians to monitor and educate pregnant patients about the potential for some eruptions being a manifestation of COVID-19. ID and ObGyn experts indicate that teledermatology enhanced the interaction among healthcare providers and improved COVID-19 care. Over 40% of all dermatology consults at a tertiary care hospital were done via teledermatology. Future collaborative research involving dermatology and specialties such as ID and ObGyn could help delineate guidelines for dermatology consult in COVID-19 patients and determine cases appropriate for teledermatology.

COVID-19-associated skin manifestations which have been linked to disease severity. Such observations emanated from dermatology research, especially large series and international registry of cutaneous manifestations relating to COVID-19, and impact COVID-19 care provided by most healthcare providers. Also, research based on international registry of skin reactions from COVID-19 vaccines is having an impact across disciplines. An increased risk for severe illness from COVID-19 is encountered in pregnancy, and dermatologists" role is to urge ObGyn and other clinicians to monitor and educate pregnant patients about the potential for some eruptions being a manifestation of COVID-19. ID and ObGyn experts indicate that teledermatology enhanced the interaction among healthcare providers and improved care. Over 40% of all dermatology consults at a tertiary care hospital were done via teledermatology. Future collaborative research involving dermatology and specialties such as ID and ObGyn could help delineate guidelines for dermatology consult in COVID-19 patients and determine cases appropriate for teledermatology.

Dermatologists have played important roles in COVID-19 prevention and judicious management of skin disease during this critical period (Bhargava et al., 2021c; Goren et al., 2020a; Goldust et al., 2020a) . They served on the frontline in several parts of the globe (Bhargava et al., 2020b; Zheng and Lai, 2020) . Most importantly, dermatologists have been focusing on demystifying the skin manifestations relating to COVID-19 as well as diagnosing and treating adverse effects of a plethora of drugs that have been utilized to treat the disease (Bhargava et al., 2021c; Galván Casas C et al., 2020) . Additionally, they have been involved in the management of occupational disease caused by personal protective equipment (Bhargava et al., 2020a; Goldust et al., 2020b; Bhargava et al., 2021b) . Furthermore, they assessed the risks associated with using systemic immunosuppressants and immunomodulators for inflammatory skin disease during the pandemic (Price et al., 2020; Sadoughifar et al., 2020) .

Dermatology research helped evaluate the prevalence and types of cutaneous manifestations relating to COVID-19; also, their duration and association of such with disease severity. The creation of international registries on skin manifestations relating to COVID-19 was a major contribution (Freeman et al., 2020a; McMahon et al., 2020b) . Also, dermatologists have investigated the role of androgens in COVID-19. An observational study reported that 71% of Caucasian males admitted to two Spanish hospitals for COVID-19 were diagnosed with androgenetic alopecia; this prevalence was higher than would be expected in the population (Goren et al., 2020) . Findings of several subsequent studies led to the hypothesis that antiandrogen drugs might have a protective effect against severe COVID-19 . This research paves the way for future clinical research investigating anti-androgen drugs for COVID-19.

COVID-19 care requires a team approach, and dermatologists may collaborate with other specialties, especially infectious disease (ID) medicine and obstetrics and gynecology (ObGyn) at every stage of the infection process. Perspectives of ID experts are included in this article. ObGyn providers have collaborated with dermatologists on COVID-19 care especially as cutaneous manifestations of COVID-19 present a diagnostic challenge in pregnant patients. In this article, we present a comprehensive overview of dermatology contributions to COVID-19 care and research. Also, we comment on the interface and potential collaboration between dermatology and other specialties, especially ID and ObGyn, in COVID-19 care and research.

Soon after the spread of COVID-19 worldwide, reports of cutaneous manifestations related to the disease appeared (Recalcati, 2020) . In an early study of COVID-19 patients in Italy, 20.4% developed cutaneous manifestations, ranging from erythematous rash to widespread urticaria (Recalcati, 2020) . However, in a meta-analysis, cutaneous manifestations had a prevalence rate of 5.69% among COVID-19 patients (Rajan et al., 2020) .

A broad spectrum of cutaneous manifestations has been detected in COVID-19 patients.

Some of the most common manifestations include acral lesions, maculopapular eruption, and urticarial eruption. Less common manifestations include vaso-occlusive, such as fixed livedo racemosa, retiform purpura, acral ischemia, and erythema multiforme-like eruptions (Daneshgaran et al., 2020) . Most manifestations have preceded other COVID-19 symptoms.

However, chilblain-like eruption may develop late in the disease process, while vesicular and maculopapular eruptions and acral lesions may occasionally predate COVID-19 symptoms.

Papulosquamous lesions lasted a median 20 days, which was the longest duration of all cutaneous manifestations in a registry of cases (Mcmahon et al., 2021b) . Pernio-like lesions lasted a median of 15 days. The study concluded that urticarial and morbilliform eruptions were relatively ephemeral, whereas papulosquamous and pernio-like eruptions were longer-lasting.

Associations between type of symptom and COVID-19 severity have been observed, with vasculitic (palpable purpura) and livedo racemosa-like patterns being associated with high severity, and chilblain-like pattern with asymptomatic status. (Marzano et al., 2021) .

There have been a large number of reports of acral pernio-like ("pseudo-chilblains") lesions associated with COVID-19, especially among younger populations, unrelated to cold exposure. Pernio-like was the most frequent lesion identified (40.4% of cases) in a systematic review (Daneshgaran et al., 2020) . In an international registry, pernio-like lesions accounted for 18% of cutaneous manifestations among laboratory-confirmed COVID-19 patients (Freeman et al., 2020a) . In an earlier study of the same registry, pernio-like lesions accounted for 63% of dermatologic manifestations among patients with suspected or confirmed COVID-19, though most cases were in patients with suspected COVID-19 without confirmatory testing (Freeman et al., 2020b) . Most pernio-like lesions occur in the feet (>80%), with smaller percentages on both feet and hands or only the hands (Freeman et al., 2020b; Piccolo et al., 2020) .

Debate exists surrounding the legitimacy of the association between acral pernio-like lesions and COVID-19. In two case series of patients presenting with pernio-like lesions during the COVID-19 pandemic, one including children only and another adults, none of the patients tested positive for COVID-19 (Caselli, Chironna et al. 2020; Herman, Peeters et al. 2020 ).

However, a case-control study comparing patients with pernio-like lesions versus controls found a significant positive odds ratio (OR) of a positive IgG against the receptor-binding domain of with controls (Ortega-Quijano et al., 2021).

Maculopapular eruptions make up to 44% of skin manifestations in an international registry of dermatologic manifestations in confirmed or suspected COVID-19 patients (Freeman et al. 2020a) . In a large Spanish cohort, they accounted for 47% of all cutaneous manifestations, while only 21.3% in a systematic review (Daneshgaran et al., 2020) .

Maculopapular eruptions associated with COVID-19 have been observed to follow morbilliform, purpuric, erythema multiforme-like, pityriasis rosea-like, erythema elevatum diutinum-like, and perifollicular patterns . Of these, generalized morbilliform eruptions have been most frequently observed .

Urticarial eruptions were first reported in relation to COVID-19 in an Italian study in which they accounted for 16.7% of skin manifestations among hospitalized COVID-19 patients (Recalcati, 2020) . In a larger study conducted in Spain, 19% of patients with suspected or confirmed COVID-19 presented with urticarial eruption . The presentation of urticarial eruptions is variable. In a meta-analysis including 202 cases of urticarial eruptions associated with COVID-19, the differential diagnoses included urticaria, urticarial vasculitis, idiopathic plantar hidradenitis, and neutrophilic dermatosis (Algaadi, 2020) .

Urticarial eruptions are mainly distributed on the trunk or in a generalized pattern, but have been also observed in facial and acral regions (Algaadi, 2020) . COVID-associated urticarial rash has been successfully treated with antihistamines, and systemic and topical steroids (Algaadi, 2020) . However, COVID-related urticaria may be difficult to distinguish from idiopathic urticaria and urticarial eruptions triggered by other infections, foods, drugs, and emotional stress (Antia et al., 2018) .

Cutaneous vasculitis has been observed in patients with COVID-19, though not commonly. In an international registry of dermatologic manifestations in confirmed or suspected COVID-19 patients, palpable purpura and vasculitis accounted for 1.4% of manifestations (Freeman et al. 2020b) . Several cases of cutaneous small vessel vasculitis in COVID-19 patients have been documented, often accompanied by palpable purpura (Dominguez-Santas et al., 2020; Mayor-Ibarguren et al., 2020; Schenker et al., 2021; Tahir et al., 2020) . More specifically, leukocytoclastic vasculitis in COVID-19 patients has been observed in both children and adults (Iraji et al., 2021; Kumar et al., 2021) . Henoch-Schonlein purpura associated with COVID-19 infection has been reported (AlGhoozi and AlKhayyat, 2021).

Livedo-like lesions relating to COVID-19 are relatively uncommon. A review study reported that vascular eruptions resembling livedo or pupura accounted for only 4% of skin manifestations and occurred mainly in elderly patients (Marzano et al., 2021) . In an international registry of dermatologic manifestations in confirmed or suspected COVID-19 patients, livedo reticularis-like lesions and livedo racemosa accounted for 3.5% and 0.6% of manifestations, respectively (Freeman et al. 2020b) . In a Spanish cohort, 6% of patients with suspected or confirmed COVID-19 presented with livedo-like lesions or necrosis, while in a French observational study, only one out of 14 COVID-19 patients with cutaneous symptoms displayed livedo-like lesions Bouaziz et al., 2020) .

The pathologic mechanisms causing skin lesions in COVID-19 patients have not been adequately elucidated. To enter cells, the spike protein of the SARS-CoV-2 virus binds to the cell membrane angiotensin-converting enzyme 2 (ACE2) receptor and the transmembrane protease serine 2 (TMPRSS2) expressed on the surface of human cells (Hoffmann et al., 2020) . ACE2 receptor expression has been observed in skin tissues, particularly in keratinocytes, as well as in the testes, kidney, colon, lung (Xue et al., 2021) . A direct pathogenic effect of SARS-CoV-2 via ACE2 receptor in the epidermis, leading to acantholysis and dyskeratosis causing visible cutaneous manifestations of infection, has been proposed (Mahe et al., 2020) . Upregulation of bradykinin, a potent vasodilator typically degraded by ACE2, results in increased vascular permeability and may be involved in edematous and/or urticarial-looking lesions (Kroumpouzos, 2021) . Activation of bradykinin receptors has a pro-inflammatory effect which may contribute to COVID-19 disease severity and lead to inflammatory cutaneous manifestations such as pernio-like lesions (Ehrenfeld et al., 2006; Kenne et al., 2019) .

Increased vascular permeability combined with complement activation by SARS-CoV-2 could also contribute to cutaneous manifestations of COVID-19. In a case series, significant deposits of terminal complement components C5b-9, C4d, and mannose binding lectinassociated serine protease 2 consistent with sustained, systemic activation of complement pathways was observed in retiform purpura (Magro et al., 2020) . Other authors suggested that an overactive immune response may be driving cutaneous manifestations of COVID-19. The release of pro-inflammatory cytokines, often called "cytokine storm", could reach the skin and stimulate dermal inflammatory cells thus triggering erythematous and urticarial eruptions (Kaya et al., 2020) . In a case series, robust interferon signaling and inflammation characterized by pronounced histiocytic infiltration, was detected in samples of pernio-like lesions (Magro et al., 2020) .

To our knowledge, sex differences in the incidence and presentation of cutaneous manifestations relating to COVID-19 have not been reported. Interestingly, sex differences in the immune reposnse to COVID-19 have been reported. In a study of patients with moderate COVID-19 who had not received immunomodulatory medications, male patients had higher plasma levels of innate immune cytokines and a more robust induction of non-classical monocytes, while female patients mounted significantly more robust T-cell activation (Takahashi et al., 2020) . Also, in a prospective study of hospitalized patients with COVID-19, the levels of several cytokines, particularly IL-4, were higher in male than in female patients, but the difference did not reach significance (Petrey et al., 2021) . Based on these immunologic findings, cutaneous manifestations of COVID-19 might disproportionately affect males or females, or at different points in disease progression. However, data are insufficient, and further research on sex differences in COVID-19 relating cutaneous manifestations is warranted.

Dermatologists have studied skin reactions observed after COVID-19 vaccination that helped ease public anxiety. A major contribution was the establishment of a registry that included 414 

COVID-19 is a protean disease and often requires a team approach for both the diagnosis and the management of the infection and its complications. In this regard, Infectious Diseases physicians and dermatologists may collaborate at every stage of the infection process.

Importantly, cutaneous manifestations may occur early in COVID-19, making appropriate dermatologic identification critical for early diagnosis and, although most patients have cutaneous signs at the same time as or after systemic symptoms, skin manifestations can be the presenting sign of COVID-19 infection in a significant percentage of patients, as high as 10-17% in some reports Young and Fernandez 2020; Zhao et al., 2020; Visconti et al., 2021) .

Importantly, timely diagnosis of skin lesions can help with COVID-19 diagnosis and management. Consultation with dermatology is useful because COVID-19-related rashes can be similar to other viral exanthems or even medication-related reactions (Young and Fernandez 2020; Tan et al., 2021) . Notably, one instructive study collected photographs of rashes from patients with a positive SARS-CoV-2 test or typical COVID-19 symptoms and had four dermatologists independently assess whether the rash was COVID-19-related. All four dermatologists agreed on the classification 82% of the time and three out of four agreed 96% of the time, indicating high diagnostic precision among the dermatologists (Visconti et al., 2021) .

There is also prognostic value in appropriately identifying different types of COVID-19associated skin manifestations, which have been linked to disease severity (Naderi-Azad and Vender, 2021). The presence of skin findings itself does not seem to be correlated with severity, but there are prognostic implications with specific types of skin lesions. Vascular lesions, like acral ischemia or livedoid eruptions, tend to affect older patients and are associated with increased ICU admissions and mortality (Young and Fernandez, 2020) . On the other hand, pseudo-chilblain lesions were most common in young adults and had the highest survival rates among COVID-19 patients with cutaneous manifestations Lai et al., 2020; Young and Fernandez 2020; Jamshidi et al., 2021) . Both vascular and pseudo-chilblain lesions can present on acral surfaces but are on the opposite sides of the spectrum in terms of predicting disease progression and severity (Tan et al., 2021) .

In addition to diagnosis and clinical evaluation, the management of skin lesions also often requires a group approach. For example, antihistamines have been used for urticaria-like lesions while systemic glucocorticoids for vascular lesions (Rahimi and Tehranchinia 2020; Jamshidi et al., 2021; Tan et al., 2021) . Taken in their totality, we see that due to the multisystem effects of COVID-19, a multidisciplinary approach is often needed in order to optimize care. In fact, COVID-19 patients can make up a significant portion of inpatient dermatology consultsone study found that over 30% of dermatology consults at a tertiary care hospital were for COVID-19 patients and over 40% of all dermatology consults were done via telemedicine (Trinidad et al., 2020; Uzuncakmak et al., 2020; Bhargava et al., 2021a) .

Teledermatology, which has become increasingly common since the start of the pandemic, can both increase access to dermatologic care for inpatients and reduce the risk of infection spread (Trinidad et al., 2020; Bhargava et al., 2020c) . However, teledermatology has been linked with lower rates of diagnostic certainty, necessitating follow-up in-person consults for as many as 25% of patients in one study (Rogers et al., 2021) . Future research with collaboration by dermatology and ID could help further delineate guidelines for dermatology consult in COVID-19 patients and determine cases appropriate for teledermatology.

Pregnant women are more susceptible to viral respiratory infections due to immunologic and physiological adaptations of pregnancy (Dotters-Katz et al., 2020) . The influenza pandemic of 2009 showed that pregnant women experienced a higher mortality compared with non-pregnant women of the same age (Mosby et al., 2011) . Two recently published multinational cohort studies have confirmed that COVID-19 in pregnancy is also associated with substantial increases in severe maternal and neonatal morbidity and mortality (Villar et al., 2021; Brandt et al., 2021) . Pregnant women are at an increased risk for severe illness from COVID-19 compared with non-pregnant women due to altered physiology, increased susceptibility to infections, and compromised immunological functions during gestation (Dashraath et al., 2020) Also, there is also an increased risk of preeclampsia, pre-term birth and other fetal complications that are possibly related to cytokine dysregulation (Alberca et al., 2020) . Hence, it is most important for all clinicians who encounter pregnant women to be able to diagnose this condition promptly.

As described above, cutaneous manifestations of COVID-19 are frequently present in our patients. it is important that there is an effective dialogue and avenue of communication between ObGyn and Dermatology as the onset of COVID-19 relating cutaneous manifestations may be the earliest clue to the presence of systemic manifestations of the viral syndrome, and prompt recognition of such can help improve maternal and fetal outcomes in this context. Also, herpes zoster may be a sign of COVID-19 in pregnancy (Elsaie et al., 2020) . This observation validates the link between pregnancy and a higher risk of COVID-19 complications.

Dermatologists" role is to urge clinicians to monitor and educate pregnant patients about the potential for rashes such as herpes zoster to be a symptom of COVID-19.

Healthcare providers who care for pregnant women are accustomed to routinely examining the skin to look for signs of clinical conditions such as any viral illnesses, atopic eruption of pregnancy, polymorphic eruption of pregnancy (PEP), intrahepatic cholestasis of pregnancy, pemphigoid gestationis and impetigo herpetiformisa number of these skin conditions are associated with adverse maternal and especially fetal outcomes (Mehta et al., 2016) . The hormonal and immune changes of gestation could affect COVID-19 cutaneous manifestations (Proietti et al., 2020) . A case of PEP that developed simultaneously with SARS-CoV-2 manifestations of fever, headache and diarrhea in a patient with COVID-19 prompted speculation that PEP could be a COVID-19 manifestation (Proietti et al., 2020) . The authors suggested that a hypersensitivity reaction against viral antigens might be a possible pathogenetic mechanism in their case. Erythematous and papular skin eruption associated with SARS-CoV-2 infection has been documented in a pregnant woman, but at the time of review, no case reports or studies have reported on the prognostic value of skin lesions in pregnant women with COVID-19 (Oropeza Chavez et al., 2021) . Further investigation is required, and ongoing collaboration between Dermatology and Obstetric Medicine would be essential to such research.

During the ongoing COVID-19 pandemic, a number of routine clinical obstetric visits were switched over to telehealth visits. This made routine examination a lot more difficult, but a number of women experienced cutaneous manifestations which were visible to the clinician via videoconferencing. On a number of occasions, dermatology expertise was sought very soon afterwards to confirm whether the cutaneous manifestations were related to COVID-19. A successful collaboration between Dermatology and ObGyn on a COVID-19-related eruption that presented in the immediate postpartum period was reported (Paolino G et al., 2020) . A number of patients also presented to the Emergency Room of the specialty maternity hospital Women & Infants" of Rhode Island during the pandemic with unexplained cutaneous manifestations. Once again, dermatological expertise was extremely valuable in differentiating between possible COVID-19 manifestations versus the other diagnoses listed above. Dermatology consultations helped optimize obstetric care greatly in these patients.

ObGyn providers should promptly provide the relevant obstetric and/or gynecological history to dermatologists in order to facilitate the appropriate diagnosis of a skin eruption. This is particularly useful for teledermatology consultations where the dermatologist may not have access to detailed ObGyn history data (Betancourt et al., 2020) . ObGyn may also provide information about a pregnant patient's COVID-vaccination status as well as any recent exposures to SARS-CoV-2 that can aid the dermatologist in establishing a diagnosis of a skin eruption.

Furthermore, ObGyn providers encounter a number of non-pregnant patients in their practice. It has been reported that women with polycystic ovarian syndrome (PCOS) have an increased risk of COVID-19 compared to those without PCOS (Subramanian et al., 2021) . The hallmarks of PCOS are insulin resistance and hyperandrogenism. It has also been reported that hyperandrogenic women experienced more severe COVID-19 symptoms (Cadegiani et al., 2021) . A possible explanation is related to hyperandrogenism being associated with an increased ACE-2 receptor expressions (La Vignera et al., 2020) . Nevertheless, a recent report showed no evidence for an increased risk of COVID-19, hospitalization, or mortality in women with acne vulgaris, PCOS, or hirsutism (Yale et al., 2010) . The study, however, provided no clear data on the clinical symptoms for which their patients were hospitalized. Ongoing collaboration between Dermatology and Gynecology may provide insight on the role of sex hormones on disease incidence and severity that will contribute to better understanding of atrisk populations (Yale et al., 2010) .

Dermatologists have played important roles in COVID-19 prevention and judicious management of skin disease during this pandemic. They have been focusing on demystifying the skin manifestations relating to COVID-19 and conducted prolific research in this field. A multidisciplinary approach with ID and ObGyn is essential to optimizing care in many COVID-19 patients.

The authors have no conflicts of interest. Eleftherios Mylonakis was involved in clinical trials on COVID-19. These trials were supported by Regeneron, NIH, and SciClone Pharmaceuticals, Inc. All funds were to the institution, and Eleftherios Mylonakis has received no direct funds.

None.

All persons designated as authors contributed substantially to this work to take public responsibility for appropriate portions of the content. Furthermore, each author certifies that this material or similar material has not been and will not be submitted to or published in any other publication before its appearance in International Journal of Women's Dermatology. All authors have read and approved the final version to be published.

Pregnancy, viral infection, and COVID-19

Urticaria and COVID-19: A review

A child with Henoch-Schonlein purpura secondary to a COVID-19 infection

Urticaria: A comprehensive review: Treatment of chronic urticaria, special populations, and disease outcomes

The Impact of COVID-19 on telemedicine utilization across multiple service lines in the United States

Protection comes at a cost: doctor's life inside personal protection equipment

Impact of COVID-19 pandemic on dermatology practice: results of a web-based, global survey

Availability of personal protective equipment (PPE) among dermatologists in the COVID-19 pandemic: assessment and risk factors in a web-based, global study

Online ahead of print

Employing dermatologists on the frontline against COVID-19: All hands on deck

Mental distress in dermatologists during COVID-19 pandemic: Assessment and risk factors in a global, cross-sectional study

Global impact on dermatology practice due to COVID-19

Online ahead of print

Vascular skin symptoms in COVID-19 : a French observational study

Epidemiology of coronavirus disease 2019 in pregnancy: risk factors and associations with adverse maternal and neonatal outcomes

No evidence of SARS-CoV-2 infection by polymerase chain reaction or serology in children with pseudochilblain

Maculopapular eruptions associated to COVID-19: A subanalysis of the COVID-Piel study

Cutaneous manifestations of COVID-19: an evidencebased review

Coronavirus disease 2019 (COVID-19) pandemic and pregnancy

Cutaneous small-vessel vasculitis associated with novel 2019 coronavirus SARS-CoV-2 infection (COVID-19)

Considerations for obstetric care during the COVID-19 pandemic

Activation of kinin B1 receptors induces chemotaxis of human neutrophils

Herpes zoster may be a marker for COVID-19 infection during pregnancy

The spectrum of COVID-19-associated dermatologic manifestations: an international registry of 716 patients from 31 countries

Pernio-like skin lesions associated with COVID-19: a case series of 318 patients from 8 countries

Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases

Use of face masks in dermatology department during the COVID-19 outbreak

Update on COVID-19 effects in dermatology specialty

Safety measures in dermatology help minimize spread of COVID-19

Anti-androgens may protect against severe COVID-19 outcomes: results from a prospective cohort study of 77 hospitalized men

A preliminary observation: Male pattern hair loss among hospitalized COVID-19 patients in Spain -A potential clue to the role of androgens in COVID-19 severity

Evaluation of chilblains as a manifestation of the COVID-19 pandemic

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

Cutaneous leukocytoclastic vasculitis secondary to COVID-19 infection: a case report

Skin manifestations in COVID-19 patients: are they indicators for disease severity? A systematic review

Clinical and histopathological features and potential pathological mechanisms of skin lesions in COVID-19: review of the literature

Neutrophils engage the kallikrein-kinin system to open up the endothelial barrier in acute inflammation

Cutaneous manifestations of COVID-19: an unusual presentation with edematous plaques and pruritic, erythematous papules, and comment on the role of bradykinin storm and its therapeutic implications

Leucocytoclastic vasculitis secondary to COVID-19 infection in a young child

Sex-specific SARS-CoV-2 mortality: among hormone-modulated ACE-2 expression, risk of venous thromboembolism and hypovitaminosis D

Extra-respiratory manifestations of COVID-19

Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases

Histology of skin lesions establishes that the vesicular rash associated with COVID-19 is not 'varicellalike

The clinical spectrum of COVID-19-associated cutaneous manifestations: an Italian multicenter study of 200 adult patients

Cutaneous small vessel vasculitis secondary to COVID-19 infection: a case report

Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: A registry-based study of 414 cases

Long COVID in the skin: a registry analysis of COVID-19 dermatological duration

Skin disease in pregnancy: the approach of the obstetric medicine physician

pandemic influenza A (H1N1) in pregnancy: a systematic review of the literature

Lessons from the first wave of the pandemic: skin features of COVID-19 can be divided into inflammatory and vascular patterns

A 34-year-old woman with a diamniotic dichorionic twin pregnancy presenting with an erythematous and papular skin rash associated with SARS-CoV-2 infection

Association between COVID-19 and chilblains: a casecontrol study

Diffuse cutaneous manifestation in a new mother with COVID-19 (SARS-Cov-2)

Cytokine release syndrome in COVID-19: innate immune, vascular, and platelet pathogenic factors differ in severity of disease and sex

Chilblain-like lesions during COVID-19 epidemic: a preliminary study on 63 patients

COVID-19 and immunomodulator/immunosuppressant use in dermatology

Polymorphic eruption of pregnancy as a possible COVID-19 manifestation

A comprehensive review of cutaneous manifestations associated with COVID-19

The trend of cutaneous lesions during COVID-19 pandemic: lessons from a meta-analysis and systematic review

Cutaneous manifestations in COVID-19: a first perspective

Impact of the COVID-19 pandemic on inpatient dermatology consult patterns at a tertiary care hospital: a retrospective cohort study

Dermatologic treatments in the era of COVID-19 pandemic-Data and Hypothesis

Reactive arthritis and cutaneous vasculitis after SARS-CoV-2 infection

Increased COVID-19 infections in women with polycystic ovary syndrome: a population-based study

Widespread cutaneous small vessel vasculitis secondary to COVID-19 infection

Sex differences in immune responses that underlie COVID-19 disease outcomes

Skin manifestations of COVID-19: A worldwide review

Telemedicine for inpatient dermatology consultations in response to the COVID-19 pandemic

Inpatient dermatology consultations during COVID 19 pandemic in a tertiary referral center

Maternal and neonatal morbidity and mortality among pregnant women with and without COVID-19 infection: the INTERCOVID Multinational Cohort Study

Diagnostic value of cutaneous manifestation of SARS-CoV-2 infection

High Expression of ACE2 on keratinocytes reveals skin as a potential target for SARS-CoV-2

Androgens and women: COVID-19 outcomes in women with acne vulgaris, polycystic ovarian syndrome, and hirsutism

Skin manifestations of COVID-19

COVID-19 and cutaneous manifestations: a systematic review

Dermatology staff participate in fight against Covid-19 in China

A novel coronavirus from patients with pneumonia in China